PE20220593A1 - Composiciones comprimidas de macitentan, metodos y usos de las mismas - Google Patents

Composiciones comprimidas de macitentan, metodos y usos de las mismas

Info

Publication number
PE20220593A1
PE20220593A1 PE2021002203A PE2021002203A PE20220593A1 PE 20220593 A1 PE20220593 A1 PE 20220593A1 PE 2021002203 A PE2021002203 A PE 2021002203A PE 2021002203 A PE2021002203 A PE 2021002203A PE 20220593 A1 PE20220593 A1 PE 20220593A1
Authority
PE
Peru
Prior art keywords
macitentan
methods
compressed compositions
list consisting
composition
Prior art date
Application number
PE2021002203A
Other languages
English (en)
Inventor
Serra João Pedro Silva
De Oliveira Ricardo Jose Camilo Ferreira
Original Assignee
Tecnimede Soc Tecnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico Medicinal Sa filed Critical Tecnimede Soc Tecnico Medicinal Sa
Publication of PE20220593A1 publication Critical patent/PE20220593A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referido a una composicion comprimida que comprende una cantidad terapeuticamente eficaz de macitentan; un diluyente de alcohol de azucar seleccionado de una lista que consiste en: maltitol, xilitol, entre otros; un tensioactivo seleccionado de una lista que consiste en: dodecilsulfato de sodio, polisorbato 80 o una mezcla de los mismos. Tambien se refiere a procedimiento para preparar dicha composicion y su uso en el tratamiento de hipertension arterial pulmonar.
PE2021002203A 2019-07-05 2020-07-03 Composiciones comprimidas de macitentan, metodos y usos de las mismas PE20220593A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT11563219 2019-07-05
EP19185065 2019-07-08
PCT/IB2020/056304 WO2021005478A1 (en) 2019-07-05 2020-07-03 Compressed macitentan compositions, methods and uses thereof

Publications (1)

Publication Number Publication Date
PE20220593A1 true PE20220593A1 (es) 2022-04-22

Family

ID=71899791

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002203A PE20220593A1 (es) 2019-07-05 2020-07-03 Composiciones comprimidas de macitentan, metodos y usos de las mismas

Country Status (11)

Country Link
US (1) US20220249381A1 (es)
EP (1) EP3993777A1 (es)
CN (1) CN114096239B (es)
AU (1) AU2020309223A1 (es)
BR (1) BR112022000117A2 (es)
CA (1) CA3144613A1 (es)
CL (1) CL2022000008A1 (es)
CO (1) CO2021017646A2 (es)
MX (1) MX2022000267A (es)
PE (1) PE20220593A1 (es)
WO (1) WO2021005478A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317119A (zh) * 2021-06-11 2023-05-01 瑞士商艾克泰聯製藥有限公司 用於口服投予之分散錠
EP4154873A1 (en) * 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan
WO2023128898A1 (en) * 2021-12-30 2023-07-06 Humanis Saglik Anonim Sirketi Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094781B2 (en) 2000-12-18 2006-08-22 Actelion Pharmaceuticals Ltd. Sulfamides and their use as endothelin receptor antagonists
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
NZ592528A (en) 2008-11-17 2013-05-31 Nycomed Pharma As Improved dissolution stability of calcium carbonate tablets
DE14721256T1 (de) 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
CN104411691B (zh) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
IN201641002749A (es) 2016-01-25 2017-09-15 Hetero Research Foundation
CN107913256A (zh) * 2016-10-08 2018-04-17 郑州泰丰制药有限公司 一种治疗肺动脉高压的马西替坦口腔崩解片及其制备方法
WO2018153925A1 (en) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
CN109260163A (zh) * 2018-10-07 2019-01-25 威海云睿信息科技有限公司 一种马西替坦片剂组合物

Also Published As

Publication number Publication date
US20220249381A1 (en) 2022-08-11
CN114096239B (zh) 2024-04-12
EP3993777A1 (en) 2022-05-11
CL2022000008A1 (es) 2022-10-07
CN114096239A (zh) 2022-02-25
MX2022000267A (es) 2022-02-03
CO2021017646A2 (es) 2022-01-17
WO2021005478A1 (en) 2021-01-14
CA3144613A1 (en) 2021-01-14
AU2020309223A1 (en) 2022-03-03
BR112022000117A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
PE20220593A1 (es) Composiciones comprimidas de macitentan, metodos y usos de las mismas
BR112021020335A2 (pt) Agonistas glp-1r e usos dos mesmos
AR055070A1 (es) Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso
CL2008002794A1 (es) Compuestos derivados de dihidropirimidina-2,4-(1h,3h)-diona; formas cristalinas, compuestos intermediarios; procedimiento de preparación de los compuestos intermediarios, composición farmacéutica; y su uso util para tratar hepatitis c en un mamífero.
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
AR106850A2 (es) Composición farmacéutica que comprende pimobendano, procedimiento
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
AR045900A1 (es) Compuesto glucocorticoesteroide, composiciones farmaceuticas que los contienen y su uso para el tratamiento de trastornos inflamatorios y/o alergicos.
AR069552A1 (es) Formulaciones para el tratamiento de semillas y metodos de uso
CL2010000233A1 (es) Combinacion fungicida que comprende fluoxastrobin y metalaxil-m y usos de la misma para combatir hongos fitopatogenos indeaseados y en la obtencion de composiciones fungicidas que comprenden ademas agentes extendedores y/o surfactantes (divisional sol. 2673-05).
AR055657A1 (es) Composiciones fungicidas
CL2018000712A1 (es) Adyuvantes mejorados para productos agroquímicos
CL2018003178A1 (es) Composición farmacéutica
CR10495A (es) Composicion que comprende por lo menos un alcohol alifatico superior y un extracto de griffonia simplicifolia
ECSP077262A (es) Composicion antihistaminica
CL2011003144A1 (es) Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05).
WO2019215679A8 (en) Foam sanitizer composition
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
PE20212158A1 (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso
CO6592097A2 (es) Composiciones endoparasiticidas
CO2018010568A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2- (etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2- metilpentanoico cristalino, y sus usos
AR055658A1 (es) Composiciones fungicidas
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas